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In a recent issue of Critical Care, Müller and coworkers 
[1] report the results of an elegant experimental study in 
which they evaluated the therapeutic potential of high-
dose simvastatin (20 mg/kg) in overventilated mice. A 
decade after the landmark studies by Amato and the 
Acute Respiratory Distress Syndrome Network high-
lighted the clinical beneﬁ  t of lung-protective ventilation 
strategies, the challenge posed by ventilator-induced lung 
injury (VILI) remains far from resolved. First, the 
proportion of patients who actually receive lung-protec-
tive ventilation with tidal volumes below 8 ml/kg remains 
modest [2,3]. Second, regional atelectasis, edema or 
compliance heterogeneities in injured lungs promote over-
distension of less aﬀ  ected lung areas even with lung-pro-
tective ventilation due to redistribution of tidal volumes 
[4,5]. Th  ird, the term ‘lung-protective ventilation’ is a 
relative one. Experimental data from murine models 
suggest that just several hours of lung-protective 
ventilation in previously healthy lungs suﬃ   ce to cause 
pro-inﬂ  ammatory responses, loss of barrier function and 
histological signs of lung injury [6].
As a consequence, adjuvant pharmacological options 
that support lung-protective ventilation strategies are in 
dire need. Drugs previously approved for other indica-
tions are particularly attractive in this context, since they 
can be rapidly implemented into clinical practice. Statins 
are HMG-CoA reductase inhibitors that were initially 
introduced into clinics for their ability to reduce low 
density lipoprotein and cholesterol levels. Yet, it soon 
became evident that they exhibit considerable pleiotropy, 
that is, biological eﬀ  ects that are independent of their 
lipid lowering properties. Cardiovascular pleiotropic 
eﬀ  ects of statins comprise improved endothelial function 
and bioavailability of nitric oxide (NO) as well as anti-
inﬂ  ammatory, anti-oxidant and anti-coagulatory proper-
ties [7]. Th   ese pharmacological characteristics fulﬁ  ll many 
aspects of the desired proﬁ  le of an adjuvant therapy for 
VILI, in which the formation and release of inﬂ  ammatory 
mediators [8] and reactive oxygen species [9] and the 
activation of platelets [10] are considered key pathogenic 
factors. Pleiotropic eﬀ  ects on endothelial cells resulting 
in improved bioavailability of NO may be of additive 
beneﬁ   t in light of the recent identiﬁ   cation of TRPV4 
(transient receptor potential vanilloid 4) as a stretch-
sensitive Ca2+ entry channel in the pulmonary endo-
thelium that plays an indispensable role in overventi-
lation-induced hyperpermeability both in isolated lungs 
[11] and in vivo [12]. Importantly, stretch-induced 
endothelial Ca2+ inﬂ  ux via TRPV4 and subsequent lung 
vascular barrier failure are negatively regulated by 
endothelial-derived NO [13]. Improved NO bioavaila-
bility may therefore protect barrier function by inhibiting 
the critical activation of TRPV4 channels in over-
ventilated lungs.
Müller and colleagues [1] provide convincing evidence 
in support of a beneﬁ  cial eﬀ  ect of statin treatment in 
VILI. Mice overventilated for 6 hours with tidal volumes 
of 12 ml/kg showed characteristic signs of VILI, including 
recruitment of neutrophils and monocytes, release of 
inﬂ  ammatory cytokines, ultrastructural evidence of endo-
thelial cell injury, vascular hyperpermeability, and 
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© 2010 BioMed Central Ltdimpaired pulmonary gas exchange. Pretreatment of mice 
with intraperitoneal injections of 20 mg/kg simvastatin 
24 hours and 1 hour prior to the onset of mechanical 
ventilation attenuated these detrimental eﬀ  ects. As lipid 
plasma levels did not diﬀ  er between groups, this thera-
peutic beneﬁ  t was clearly attributable to the pleiotropic 
properties of statins. While these data provide principal 
proof-of-concept that statins may present a promising 
adjuvant strategy in patients undergoing mechanical 
ventilation, their translation into clinical practice requires 
careful consideration. First, the administered simvastatin 
dose of 20 mg/kg/day exceeds the currently highest 
approved clinical dose of 80 mg/day by far, thus raising 
the likelihood of serious statin-associated adverse eﬀ  ects, 
such as myopathy or interstitial lung disease, in patients. 
Second, while simvastatin treatment eﬀ  ectively attenu-
ated inﬂ   ammatory responses in the lungs, it did not 
reduce the systemic inﬂ  ammatory response to over  venti-
lation, as indicated by the unabated elevation of plasma 
cyto  kine levels and leukocytosis. As secondary injury to 
extra-pulmonary organs is considered to contribute 
critically to ventilation-dependent morbidity and mor-
tality [14], it remains to be shown whether the demon-
strated lung-protective eﬀ  ect of simvastatin can translate 
into an improved long-term clinical outcome. Last but 
not least, just as for the proven eﬀ  ectiveness of statins in 
the primary prevention of coronary heart disease [15], 
the implementation of prophylactic statin treatment 
prior to or with the onset of any mechanical ventilation 
may simply not be aﬀ  ordable or cost-eﬀ  ective on a larger 
scale.
Regardless of these concerns currently opposing the 
rapid clinical implementation of statin prevention for 
mechanical ventilation, the auspicious concept of 
adjuvant pharmacological therapy in support of lung-
protective ventilation deserves in-depth evaluation and 
scientiﬁ  c pursuit with the aim to either overcome these 
limitations or to identify superior alternative adjuvant 
pharmaceuticals.
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